Audio Medica - Medical Audio News Interviews & Podcasts » ICAAC 2005

Audio Journal of Infectious Disease: Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco

admin — Thu, 28 Sep 2006 11:42:47 +0000

Roger Baxter

Jaap van Dissel

Which Antibiotics Pose Greatest Risk of C. difficile infection?

REFERENCE: Abstract K-0349
Roger Baxter, Kaiser Permanente, Oakland
In the presence of certain antibiotics, it seems Clostridium difficile can flourish. Roger Baxter, from Kaiser Permanente in Northern California, presented data suggesting that imipenem and clindamycin are among the drugs that give patients a greater risk of C. difficile infection.

Prevent C. difficile relapse – with a Protein Concentrate from Cows

REFERENCE: Abstract K-0352
Jaap van Dissel, Leiden University Medical Center
Clostridium difficile relapse is sometimes difficult to prevent with antibiotics – so could a rather different approach, involving a protein powder obtained from immunised cows, give a greater and more durable benefit? Jaap van Dissel of the Leiden University Medical Center had the details at ICAAC.

Fire Ants: Purveyors of Pain, or Possible Source of New Antimicrobials?

admin — Sat, 07 Jan 2006 22:51:04 +0000

Heather White

Heather White, University of Mississippi Medical Center, Jackson
If you have ever been bitten by a fire ant you’ll remember the pain! But a study presented in Washington has shown that when they sting, they produce substances with antimicrobial properties. And hence these fierce creatures could have a use in medicine.

Click here for all the interviews from ICAAC 2005

Latest on Human Papilloma Virus Vaccine for Cervical Cancer

admin — Sat, 07 Jan 2006 22:45:19 +0000

John Schiller

John Schiller, National Cancer Institute, Bethesda
The human papilloma virus vaccine, which is currently being tested in the prevention of cervical cancer, brings together both infectious disease and cancer. Delegates at the ICAAC conference heard an update on both the anti-cancer and the anti-wart activities of the two vaccines: one from Merck and the other from GlaxoSmithKline.

Click here for all the interviews from ICAAC 2005

Which Macrolide Antibiotics Provide Greatest Barrier to Resistance in Streptococcus pneumoniae?

admin — Sat, 07 Jan 2006 22:41:51 +0000

Joseph Blondeau

Antibiotic resistance is not going to go away in a hurry, but can we at least make it as difficult as possible for bacteria to overcome the drugs they face? Joseph Blondeau told the conference about his group’s investigation into which of three macrolide antibiotics was the most difficult for Streptococcus pneumoniae to develop resistance against.

Click here for all the interviews from ICAAC 2005

Pharmacokinetically Enhanced Amoxicillin and Clavulanate for Drug Resistant Streptococcus Pneumoniae

admin — Sat, 07 Jan 2006 22:36:42 +0000

Thomas File

Thomas File, Summa Health System, Akron, Ohio
Community Associated Pneumonia is a sizeable problem for health systems, and what is more, some strains of the frequent culprit - streptococcus pneumoniae - are found to be drug resistant. Thomas File told the conference about a Pharmacokinetically Enhanced regimen of Amoxicillin and Clavulanate and how it does seem to be active in patients infected with one of these resistant strains.

Click here for all the interviews from ICAAC 2005

New Antiviral Approach for Infectious Mononucleosis - Kissing Disease

admin — Sat, 07 Jan 2006 22:30:40 +0000

Hank Balfour

Hank Balfour, University of Minnesota, Minneapolis
Infectious mononucleosis, also known as the kissing disease, is caused Epstein Barr Virus, or EBV; so, can we effectively treat, and prevent its spread, with an antiviral? According to one study - with a limited number of patients - the answer might be yes. Hank Balfour told us more.

Click here for all the interviews from ICAAC 2005

Clostridium difficile: Back in Hospitals and Meaning Business

admin — Sat, 07 Jan 2006 22:20:15 +0000

Lance Peterson

Lance Peterson, Evanston Northwestern Healthcare, Illinois
The bacterium clostridium difficile that can cause diarrhoea in hospital patients is making a resurgence. It’s potentially very aggressive, and it’s not so easy to detect any more. But a new real-time polymerase chain reaction (PCR) test reported at the ICAAC conference looking for genes involved with production of the C. difficile product: toxin B promises to help fight the problem.

Click here for all the interviews from ICAAC 2005

Methicillin-Resistant Staphylococcus Aureus: New Initiatives

admin — Sat, 07 Jan 2006 22:15:21 +0000

Michele Pearson

Michele Pearson, Centers for Disease Control and Prevention, Atlanta
A community-wide approach is needed to combat MRSA according to a new assessment presented to the conference in Washington DC. An ongoing study has highlighted as paramount the value of coordinated action including simple hygiene measures such as hand-washing.

Click here for all the interviews from ICAAC 2005

Chloroquine Selects for Fluoroquinolone Resistance in Guyana

admin — Sat, 07 Jan 2006 22:03:14 +0000

Ross Davidson

Ross Davidson, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia
The use of the antimalarial chloroquine could provide the selective pressure for E.coli to develop fluoroquinolone resistance - that’s according to a study presented by Ross Davidson at ICAAC. He investigated this by looking at remote community from Guyana, who had access to chloroquine but not fluoroquinolones, and he began by telling Audio Medica about the link between the two.

Click here for all the interviews from ICAAC 2005

Benign Bladder Bacteria: Preventing Infection in Spinal Cord Injury Patients

admin — Sat, 07 Jan 2006 12:04:59 +0000

Barbara Trautner

Barbara Trautner, Baylor College of Medicine, Houston
When patients with spinal cord injury rely on urinary catheters for bladder drainage, this may lead to one or more urinary tract infections, or UTIs. As an alternative to drugs, delegates at ICAAC heard about a rather more novel technique for dealing with this problem: bacterial interference: using benign bacteria to out-compete the pathogens.

Click here for all the interviews from ICAAC 2005